PRTN3 and rheumatoid arthritis: Synovial biopsies were collected from fourteen methotrexate-resistant RA patients (median disease duration 11.7 years, ACPA/RF positivity: 57%, erosive disease: 86%), before and 16 weeks after treatment with abatacept 125 mg per week subcutaneously.